Enhanced bioavailability of verapamil after oral administration with hesperidin in rats

Article
First Online:
Received:

Abstract

The aim of this study was to investigate the effects of hesperidin on the pharmacokinetics of verapamil and its major metabolite, norverapamil, in rats. The pharmacokinetic parameters of verapamil and norverapamil in rats were measured after the oral administration of verapamil (9 mg/kg) in the presence or absence of hesperidin (3 or 10 mg/kg). Compared to the control group, the presence of hesperidin significantly (p<0.01) increased the area under the plasma concentration-time curve (AUC) of verapamil by 71.1–96.8% and the peak concentration (Cmax) of verapamil by 98.3–105.2%. Hesperidin significantly (p<0.01) decreased the total plasma clearance (CL/F) of verapamil by 41.6–49.2% in rats. However there was no significant change in the time to reach the peak plasma concentration (Tmax), the elimination rate constant (Kel) and the terminal half-life (T1/2) of verapamil in the presence of hesperidin. The AUC and Cmax of norverapamil were significantly (p<0.05) higher in rats coadministrated with hesperidin than those of the control. Consequently hesperidin significantly enhanced bioavailability of verapamil in rats. These results might be due to the decreased efflux and metabolism of verapamil in the intestine. Drug interactions should be concerned in the clinical setting when verapamil is used concomitantly with hesperidin or hesperidin-containing dietary.

Key words

Verapamil Norverapamil Hesperidin Pharmacokinetics Bioavailability Rats 
This is a preview of subscription content, log in to check access.

References

  1. Adachi, Y., Suzuki, H., and Sugiyama, Y., Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm. Res., 18, 1660–1668 (2001).PubMedCrossRefGoogle Scholar
  2. Ameer, B., Weintraub, R. A., Johnson, J. V., Yost, R. A., and Rouseff, R. L., Flavanone absorption after naringin, hesperidin, and citrus administration. Clin. Pharmacol. Ther., 60, 34–40 (1996).PubMedCrossRefGoogle Scholar
  3. Bobrowska-Hagerstrand, M., Wrobel, A., Mrowczynska, L., Soderstrom, T., Shirataki, Y., Motohashi, N., Molnar, J., Michalak, K., and Hagerstrand, H., Flavonoids as inhibitors of MRP1-like efflux activity in human erythrocytes. A structure—activity relationship study. Oncol. Res., 13, 463–469 (2003).PubMedGoogle Scholar
  4. Bok, S. H., Lee, S. H., Park, Y. B., Bae, K. H., Son, K. H., Jeong, T. S., and Choi, M. S., Plasma and hepatic cholesterol and hepatic activities of 3-hydroxy-3-methyl-glutaryl-CoA reductase and acyl CoA: cholesterol transferase are lower in rats fed citrus peel extract or a mixture of citrus bioflavonoids. J. Nutr., 129, 1182–1185 (1999).PubMedGoogle Scholar
  5. Borradaile, N. M., Carroll, K. K., and Kurowska, E. M., Regulation of HepG2 cell apolipoprotein B metabolism by the citrus flavanones hesperetin and naringenin. Lipids., 34, 591–598 (1999).PubMedCrossRefGoogle Scholar
  6. Choi, J. S. and Burm, J. P., Enhanced nimodipine bioavailability after oral administration of nimodipine with morin, a flavonoid, in rabbits. Arch. Pharm. Res., 29, 333–338 (2006).PubMedCrossRefGoogle Scholar
  7. Choi, J. S. and Han, H. K., Pharmacokinetic interaction between diltiazem and morin, a flavonoid, in rats. Pharmacol. Res., 52, 386–391 (2005).PubMedCrossRefGoogle Scholar
  8. Choi, J. S. and Han, H. K., The effect of quercetin on the pharmacokinetics of verapamil and its major metabolite, norverapamil, in rabbits. J. Pharm. Pharmacol., 56, 1537–1542 (2004).PubMedCrossRefGoogle Scholar
  9. Doppenschmitt, S., Spahn-Langguth, H., Regardh, C. G., and Langguth, P., Role of P-glycoprotein-mediated secretion in absorptive drug permeability: An approach using passive membrane permeability and affinity to P-glycoprotein. J. Pharm. Sci., 88, 1067–1072 (1999).PubMedCrossRefGoogle Scholar
  10. Eichelbaum, M., Mikus, G., and Vogelgesang, B., Pharmacokinetics of (+)-, (−)-and (±)-verapamil after intravenous administration. Brit. J. Clin. Pharmacol., 17, 453–458 (1984).Google Scholar
  11. Eichelbaum, M., Remberg, E. G., Schomerus, M., and Dengler, H. J., The metabolism of D,L(14C) verapamil in man. Drug Metab. Dispos., 7, 145–148 (1979).PubMedGoogle Scholar
  12. Fleckenstein, A., Specific pharmacology of calcium in myocardium, cardiac pacemakers, and vascular smooth muscle. Ann. Rev. Pharmacol. Toxicol., 17, 149–166 (1977).CrossRefGoogle Scholar
  13. Fuhr, U., Muller-Peltzer, H., Kern, R., Lopez-Rojas, P., Junemann, M., Harder, S., and Staib A. H. Effects of grapefruit juice and smoking on verapamil concentrations in steady state. Eur. J. Clin. Pharmacol., 58, 45–53 (2002).PubMedCrossRefGoogle Scholar
  14. Garg, A., Garg, S., Zaneveld, L. J. D., and Singla, A. K., Chemistry and pharmacology of the citrus bioflavonoid hesperidin. Phytother. Res., 15, 655–669 (2001).PubMedCrossRefGoogle Scholar
  15. Gottesman, M. M. and Pastan, I., Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem., 62, 385–427 (1993).PubMedCrossRefGoogle Scholar
  16. Gould, B. A., Mann, S., Kieso, H., Bala Subramanian, V., and Raftery, E. B., The 24-hour ambulatory blood pressure profile with verapamil. Circulation., 65, 22–27 (1982).PubMedGoogle Scholar
  17. Hodek, P., Trel, P., and Stiborova, M., Flavonoids-potent and versatile biologically active compounds interacting with cytochromes P450. Chem. Biol. Interact., 139, 1–21 (2002).PubMedCrossRefGoogle Scholar
  18. Kim, H. J. and Choi, J. S., Effects of naringin on the pharmacokinetics of verapamil and one of its metabolites, norverapamil, in rabbits. Biopharm. Drug. Dispos., 26, 295–300 (2005).PubMedCrossRefGoogle Scholar
  19. Korthuis, R. J. and Gute, D. C., Adhesion molecule expression in postischemic microvascular dysfunction: activity of a micronized purified flavonoid fraction. J. Vasc. Res., 36, 15–23 (1999).PubMedCrossRefGoogle Scholar
  20. Lewis, G. R., Morley, K. D., Lewis, B. M., and Bones, P. J., The treatment of hypertension with verapamil. NZ. Medical. J., 87, 351–354 (1978).Google Scholar
  21. Ross, J. A. and Kasum, C. M., Dietary avonoids: bioavailability, metabolic effects, and safety. Annu. Rev. Nutr., 22, 19–34 (2002).PubMedCrossRefGoogle Scholar
  22. Schomerus, M., Spiegelhaider, B., Stieren, B., and Eichelbaum, M., Physiologic disposition of verapamil in man. Cardiovasc. Res., 10, 605–612 (1976).PubMedCrossRefGoogle Scholar
  23. Tsai, T. H. and Liu, M. C., Determination of extracellular hesperidin in blood and bile of anaesthetized rats by microdialysis with high-performance liquid chromatography: a pharmacokinetic application. J. Chromatogr. B. Analyt. Technol. Biomed. Life. Sci., 806, 161–166 (2004).PubMedCrossRefGoogle Scholar
  24. Yoshiharu, M., Hitomi, T., Hirotami, M., Mikihiko, N., Takashi, T., Hisakazu, O., and Yasufumi, S., Effect of bioflavonoids on vincristine transport across blood-brain barrier. European Journal of Pharmacology., 395, 193–201 (2000).CrossRefGoogle Scholar
  25. Zhang, S. and Morris, M. E., Effects of the avonoids biochanin A, morin, phloretin, and silymarin on P-glycoprotein-mediated transport. J. Pharmacol. Exp. Ther., 304, 1258–1267 (2003).PubMedCrossRefGoogle Scholar

Copyright information

© The Pharmaceutical Society of Korea 2008

Authors and Affiliations

  1. 1.College of PharmacyChosun UniversityGwangjuKorea

Personalised recommendations